id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-318866-3arxrm8m	Magnano, M.	Psoriasis, COVID‐19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment	2020-05-30		.txt	text/plain	694	52	52	The management of psoriatic patients under biologics during SARS-CoV-2 outbreak is of great concern, as well as the outcome of the COronaVirus DIsease (COVID-19) in this population. On a pool of 720 psoriatic patients followed by our 3 referral centers for severe psoriasis, we registered 9 swab-confirmed cases of SARS-CoV-2 infection (Table 1) . 1 , who concluded that, despite the cardiovascular and metabolic comorbidities affecting psoriatic patients and also representing risk factors for severe COVID-19, patients seldom required hospitalization. 2 The appropriateness of withdrawing biologic therapies preventively in psoriatic patients is still debated and it is also unclear whether their use influences the course of COVID-19 or not. 4 The psoriatic population treated with biologic therapies is on average young 5 , since elderly patients with multiple comorbidities are usually excluded from systemic treatments. Although this case series is limited, we evidenced that ARDS can represent a complication also in patients under biologics.	./cache/cord-318866-3arxrm8m.txt	./txt/cord-318866-3arxrm8m.txt